Phase II and III Trials: Comparison of Four Chemotherapy Regimens in Advanced Non–Small-Cell Lung Cancer (ECOG 1594)-Reference-Cited by-同舟云学术

Phase II and III Trials: Comparison of Four Chemotherapy Regimens in Advanced Non–Small-Cell Lung Cancer (ECOG 1594)

Published:2000-08 Issue:1 Volume:2 Page:21-22
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

CIG Media Group

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference7 articles.

1. An update on North American randomized studies in non-small cell lung cancer;Bunn;Semin Oncol,1998

2. New agents in the management of advanced non-small cell lung cancer;Carney;Semin Oncol,1998

3. Randomized phase III trial of cisplatin (CDDP) vs. CDDP plus navelbine (NVB) in treatment of advanced non-small cell lung cancer (NSCLC): an update of a Southwest Oncology Group study (SWOG-9308);Wozniak;Proc Am Soc Clin Oncol,1998

4. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-smallcell lung cancer;Sandler;J Clin Oncol,2000

5. Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: a report of the international CATAPULT I study group. Cisplatin and tirapazamine in subjects with advanced previously untreated nonsmall- cell lung tumors;von Pawel;J Clin Oncol,2000

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Genetic polymorphisms and platinum-induced hematological toxicity: a systematic review;Frontiers in Pharmacology;2024-08-21

2. Local Consolidative Therapy May Have Prominent Clinical Efficacy in Patients with EGFR-Mutant Advanced Lung Adenocarcinoma Treated with First-Line Afatinib;Cancers;2023-03-28

3. Toripalimab plus chemotherapy vs. chemotherapy in patients with advanced non-small-cell lung cancer: A cost-effectiveness analysis;Frontiers in Pharmacology;2023-02-14

4. Efficacy of first-line treatment with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) alone or in combination with chemotherapy for advanced non-small cell lung cancer (NSCLC) with low-abundance mutation;Lung Cancer;2019-02

5. EGFR-TKI down-regulates PD-L1 in EGFR mutant NSCLC through inhibiting NF-κB;Biochemical and Biophysical Research Communications;2015-07